Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.2K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.2K
Phase I Reactions: Reductive Reactions01:27

Phase I Reactions: Reductive Reactions

698
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
698
Drug Therapy01:28

Drug Therapy

370
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
370

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Characterization of Non-Neurogenic and Neurogenic Lower Urinary Tract Dysfunction (LUTD) in SCI-Induced and Partial Bladder Outlet Obstruction Mouse Models.

International journal of molecular sciences·2023
Same author

Stimulation of the cuneiform nucleus enables training and boosts recovery after spinal cord injury.

Brain : a journal of neurology·2022
Same author

Effects of opioids and benzodiazepines on bladder function of awake restrained mice.

American journal of clinical and experimental urology·2022
Same author

Lower urinary tract electrical sensory assessment: a systematic review and meta-analysis.

BJU international·2021
Same author

The Gigantocellular Reticular Nucleus Plays a Significant Role in Locomotor Recovery after Incomplete Spinal Cord Injury.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2020
Same author

Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial.

The Lancet. Infectious diseases·2020

Related Experiment Video

Updated: Mar 17, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

9.5K

5-Alpha-Reductase Inhibitors and Combination Therapy.

Claudius Füllhase1, Marc P Schneider2

  • 1Department of Urology, University of Rostock, Ernst-Heydemann-Str. 6, Rostock 18057, Germany.

The Urologic Clinics of North America
|August 1, 2016
PubMed
Summary
This summary is machine-generated.

5-Alpha reductase inhibitors (5ARIs) effectively treat benign prostatic hyperplasia (BPH) by reducing prostate size and improving urinary symptoms. Combination therapies with alpha-blockers or PDE5 inhibitors offer enhanced outcomes and manage side effects.

Keywords:
5-Alpha-reductase inhibitorsCombination drug therapyDutasterideFinasterideLower urinary tract symptomsProstatic hyperplasia

More Related Videos

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Experiment Videos

Last Updated: Mar 17, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

9.5K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms (LUTS).
  • 5-Alpha reductase inhibitors (5ARIs) are a key therapeutic class for managing BPH.
  • Prostate volume and severity of LUTS are critical factors in treatment selection.

Purpose of the Study:

  • To review the efficacy of 5ARIs in treating BPH.
  • To evaluate combination therapies involving 5ARIs for improved BPH management.
  • To assess the safety and suitability of 5ARIs, including for elderly patients.

Main Methods:

  • Review of pharmacological mechanisms of 5ARIs.
  • Analysis of clinical outcomes from studies on 5ARIs and combination therapies.
  • Consideration of patient-specific factors like prostate size and frailty.

Main Results:

  • 5ARIs inhibit dihydrotestosterone production, leading to prostate shrinkage and LUTS improvement, especially in larger prostates (>30-40ml).
  • 5ARIs generally have mild side effects and are considered suitable for frail elderly patients (FORTA classification).
  • Combination therapy with alpha-blockers (ABs) demonstrated superior symptomatic outcomes and reduced clinical progression risk.
  • Combining phosphodiesterase type 5 inhibitors (PDE5Is) with 5ARIs mitigates sexual side effects and enhances LUTS relief.

Conclusions:

  • 5ARIs are effective for BPH, particularly for patients with larger prostates.
  • Combination therapies, especially 5ARI/AB, offer significant benefits for symptomatic relief and disease progression.
  • Pharmacological combinations can optimize BPH treatment by addressing efficacy and side effect profiles.